QT
ARQT icon

Quantbot Technologies’s Arcutis Biotherapeutics ARQT Stock Holding History

Quantbot Technologies’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-921
Closed -$21.7K – 1919
2026
Q1 		$21.7K Sell
921
-76
-8% -$1.94K ﹤0.01% 1484
2025
Q4 		$29K Sell
997
-7,641
-88% -$196K ﹤0.01% 1548
2025
Q3 		$163K Sell
8,638
-1,678
-16% -$26.5K ﹤0.01% 1354
2025
Q2 		$145K Buy
+10,316
New +$145K ﹤0.01% 1313
2024
Q2 		– Sell
-12,200
Closed -$121K – 1419
2024
Q1 		$121K Buy
+12,200
New +$91.1K 0.01% 1127
2023
Q1 		– Sell
-14,500
Closed -$215K – 1528
2022
Q4 		$215K Buy
+14,500
New +$253K 0.02% 870
2022
Q2 		– Sell
-2,300
Closed -$44K – 1683
2022
Q1 		$44K Buy
+2,300
New +$38.9K ﹤0.01% 1223

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quantbot Technologies's ARQT Position: Q2 2026 in Review

Quantbot Technologies sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 921 shares — an estimated $21.7K sold.

Quantbot Technologies first reported a position in ARQT in Q1 2022 and held it in 7 quarters. The position peaked at $215K in Q4 2022. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Quantbot Technologies reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Quantbot Technologies sold 921 Arcutis Biotherapeutics shares in Q2 2026, an estimated $21.7K.
  • Quantbot Technologies first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 7 quarters.
  • Quantbot Technologies's Arcutis Biotherapeutics position peaked at $215K in Q4 2022.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Quantbot Technologies's 13F filing for Q2 2026, filed 12 Aug 2026.